Collection of Blood for Gene Expression/Genomic Studies in Individuals With Diabetes (Qatar)

NCT01172743 | Terminated

• 2 other identifiers: 0904010340HMC Protocol # 9093/09
• Study Type: observational
• Target: 450
• Locations: 1 country
• Sites: 1

Brief Summary

This protocol is designed to gather a small amount of blood for extraction of DNA for the study of the genetic basis of diabetes. The study population will include individuals with known diabetes, and controls without diabetes. Investigators aim to understand the genetics of diabetes, and will use the cells and serum from this blood to perform genotyping and gene expression studies of individuals with diabetes and relevant controls.

Conditions

Diabetes Mellitus; Type 2 Diabetes Mellitus

Keywords

Diabetes Mellitus; Diabetes; Type-2; Adult Onset

Study Arms (2)

Diabetes

Individuals with diabetes that fit eligibility criteria.

Normal Control

Individuals without history of diabetes.

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Diabetes group will be taken from (1)individuals visiting the Medicine Department at the Hamad Medical Corporation(HMC), Qatar for standard clinical care, (2)outpatient adult individuals seen at the HMCdiabetes clinics, (3)individuals who have participated in the following IRB protocol #s:0608008703, #0602008388 and HMC protocol #231, (4)ndividuals who attend clinics at the Qatar Diabetes Association (QDA), and (5)Individuals who work at the governmental ministries of Qatar. Controls will be obtained from volunteers without a history of diabetes. Family members of patients may be asked to participate in the study.

You may qualify if:

• Must provide informed consent
• Males and females, age 18 years and older
• Documented evidence of diabetes using at least one of the following: (1) blood tests consistent with Type-II diabetes; (2) oral glucose tolerance tests consistent with Type-II diabetes; (3) subject taking medication to treat Type-II diabetes.

You may not qualify if:

• Individual refuses consent
• Pregnant females with gestational diabetes
• Type-I diabetes
• Normal control group
• Must provide informed consent
• Males or females ages 18 years and older
• Resolved gestational diabetes
• Individual refuses consent.
• Individuals with history of diabetes.

Sponsors & Collaborators

• Weill Medical College of Cornell University: lead
• Weill Cornell Medical College in Qatar: collaborator
• Hamad Medical Corporation: collaborator

Study Sites (1)

Hamad Medical Corporation

Doha, Qatar

Location

Biospecimen

Retention: SAMPLES WITH DNA

Genomic DNA will be extracted, and genome wide SNP analysis and promoter sequences for genes will be obtained. The goal is to find single nucleotide polymorphims (SNP), small changes in single genes that affect disease risk, to see if they correlate with diabetes. Serum will be stored for future studies, for a period of 6 years, to look at levels of proteins. Subjects who consent to participate in this study will have their serum stored for up to 6 years, inorder to be used for future studies on genomics.

MeSH Terms

Conditions

Diabetes Mellitus; Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Ronald G Crystal, MD

  Weill Cornell Medical College, NY and Qatar

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 28, 2010
• First Posted: July 30, 2010
• Study Start: June 1, 2009
• Primary Completion: July 1, 2020
• Study Completion: July 1, 2020
• Last Updated: July 31, 2020

Record last verified: 2020-07

Locations

QA (1)